Merck

HIV AIDS PREP
Biotech

Merck's HIV combo treatment meets efficacy bar in phase 3 trials

Two phase 3 studies assessing a combo of Merck's approved doravirine and investigational islatravir met their primary efficacy goals.
Zoey Becker Dec 19, 2024 11:54am
Historical building and Yale university campus in downtown New Haven CT USA

Amgen, Merck join academic clinical trial diversity partnership

Sep 16, 2024 3:10pm
Male and female superheroes posing in fluttering cloaks

ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial

Sep 14, 2024 2:30am
Graphic of two hands shaking under a red and purple light

Merck to use N-Power clinical trial platform for cancer studies

Jul 1, 2024 4:20pm
Photo of a syringe and two vials labeled pneumococcal vaccine

Merck compares pneumococcal vaccine to 1983 warhorse

Apr 29, 2024 9:00am
data deal handshake

Merck inks R&D deal with Intermountain spinoff Culmination Bio

Jan 25, 2024 9:30am